Triple

T22690613
Position Surface form Disambiguated ID Type / Status
Subject BTK E561038 entity
Predicate inhibitedBy P37861 FINISHED
Object tirabrutinib — NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: tirabrutinib | Statement: [BTK, inhibitedBy, tirabrutinib]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: tirabrutinib
Context triple: [BTK, inhibitedBy, tirabrutinib]
  • A. pirtobrutinib
    Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
  • B. acalabrutinib
    Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • C. tucatinib
    Tucatinib is an oral small-molecule tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer, including cases with brain metastases.
  • D. larotrectinib
    Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
  • E. selpercatinib
    Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: tirabrutinib
Target entity description: Tirabrutinib is a selective small-molecule Bruton’s tyrosine kinase (BTK) inhibitor developed as a targeted therapy for certain B-cell malignancies and autoimmune diseases.
  • A. pirtobrutinib
    Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
  • B. acalabrutinib
    Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • C. tucatinib
    Tucatinib is an oral small-molecule tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer, including cases with brain metastases.
  • D. larotrectinib
    Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
  • E. selpercatinib
    Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2454d71b48190a1f80af9f82b6fcf completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1789a1fd08190bce5fa0babe695d3 completed April 29, 2026, 3:18 a.m.
Created at: April 17, 2026, 3:13 p.m.